HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis

Future Oncol. 2019 Jan;15(3):241-255. doi: 10.2217/fon-2018-0577. Epub 2018 Oct 11.


Chemotherapy-induced nausea and vomiting (CINV) may occur during the acute (0-24 h) or delayed (25-120 h) phase following chemotherapy administration. The addition of a neurokinin 1 receptor antagonist to antiemetic regimens containing a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone has resulted in improved CINV prophylaxis. Due to numerous adverse events and hypersensitivity reactions associated with fosaprepitant, a commonly used neurokinin 1 receptor antagonist, there remains an unmet need for better-tolerated formulations. HTX-019, the US FDA-approved polysorbate 80- and synthetic surfactant-free aprepitant injectable emulsion, is bioequivalent to and better tolerated (fewer treatment-emergent adverse events) than fosaprepitant. HTX-019 represents a valuable alternative to fosaprepitant for CINV prophylaxis.

Keywords: Cinvanti; HTX-019; aprepitant.

MeSH terms

  • Aprepitant / administration & dosage
  • Clinical Trials as Topic
  • Drug-Related Side Effects and Adverse Reactions / drug therapy*
  • Drug-Related Side Effects and Adverse Reactions / pathology
  • Humans
  • Induction Chemotherapy / adverse effects
  • Morpholines / adverse effects
  • Nausea / chemically induced
  • Nausea / drug therapy*
  • Neurokinin-1 Receptor Antagonists / administration & dosage*
  • Polysorbates / administration & dosage*
  • Receptors, Neurokinin-1 / genetics
  • Vomiting / chemically induced
  • Vomiting / drug therapy*


  • Morpholines
  • Neurokinin-1 Receptor Antagonists
  • Polysorbates
  • Receptors, Neurokinin-1
  • Aprepitant
  • fosaprepitant